Shuttle Pharmaceuticals Holdings, Inc. Price & Performance (SHPH)

Shuttle Pharmaceuticals Holdings shares have declined for five consecutive days, closing at $0.254 on April 17, 2025. The stock has dropped 36.66% over the past ten days, with technical signals remaining negative. Analysts project further declines, citing ongoing volatility and a lack of support below current price levels.1

Shuttle Pharmaceuticals recently closed a $5.75 million underwritten public offering, issuing over 19 million shares at $0.30 each—a deep discount to market. While this move dilutes existing shareholders, it secures critical funding for the company’s Phase II clinical trial on radiation sensitizers, vital for advancing cancer therapy research.23

Shuttle Pharmaceuticals has accelerated patient enrollment in its Phase II glioblastoma trial and expanded its partnership with Theradex Systems. The company also named Christopher Cooper interim Co-CEO, joining Dr. Anatoly Dritschilo, and simplified its capital structure by amending terms with Alto Opportunity Master Fund, aiming to streamline operations and research.4